SmallCapReview.com has been a leading site for information on small cap stocks, penny stocks and microcaps since 1999.
Inovio Pharmaceuticals (AMEX: INO) $0.74. Today reported data demonstrating long-term durability of T cell immune responses of up to over two years (at the latest time measured) in 7 of 8 evaluated patients following a fourth vaccination of VGX-3100, its investigational SynCon DNA Vaccine for treating cervical dysplasia and cancer caused by human papillomavirus (HPV) that is delivered using intramuscular electroporation. The data further highlights the viability of using multiple booster vaccinations with a DNA vaccine delivered using electroporation, in contrast to other non-replicating vaccine vectors that may induce unwanted immune responses against the vector after multiple vaccinations. These results were presented at DNA Vaccines 2011, hosted in San Diego by the International Society of DNA Vaccines, by Mark Bagarazzi, MD, Inovio's Chief Medical Officer.
What They Do: Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. Its SynCon vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza.
China Information Technology (Nasdaq: CNIT) $2.30. Today announced that it signed $30.4 million in new contracts during the second quarter of 2011. The Company's core IT business segment contributed 65%, or $19.8 million, of the total contract wins, while its Digital Display segment contributed 35%, or $10.6 million. The Company's second quarter contract wins came from 28 provinces and provincial cities in China.
What They Do: China Information Technology, Inc., through its subsidiaries and other consolidated entities, specializes in information technologies and display technologies.
IMAX Corporation (NYSE: IMAX) $27.97. Today announced along with AMC Entertainment Inc., an expansion of the companies' joint revenue sharing arrangement to include the installation of 10 additional IMAX theatres in the United States. These theatres, which fulfill the rollout of theatres under the June 2010 expansion of the parties' original 2007 joint revenue sharing agreement, are expected to open by the end of 2012. The 10 new IMAX theatre systems are in addition to AMC's existing obligation for 115 IMAX joint revenue sharing theatres, 105 of which are currently in operation.
The companies intend to open the new IMAX theatres in both new markets and in markets where AMC already operates IMAX theatres in North America. Upon completion of the full AMC IMAX theatre roll-out, AMC will operate 125 IMAX theatres under the joint revenue sharing agreement, and 135 in total. In June 2010, the companies amended the initial agreement to provide for the opening of 15 to 25 additional IMAX theatres.
What They Do: IMAX Corporation is one of the world's leading entertainment and technology companies, specializing in the creation and delivery of premium, awe-inspiring entertainment experiences.
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit www.SmallCapReview.com.